VIR BIOTECHNOLOGY INC (VIR)
Health Care · Clinical-stage immunology and virology therapeutics · NASDAQ
Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking technologies.
What VIR BIOTECHNOLOGY INC does
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat and prevent serious infectious diseases and cancer. The company leverages its proprietary immunology and virology platforms, including masking and targeted T-cell engagement technologies, to advance product candidates across its pipeline. Vir's programs span hepatitis delta virus, masked T-cell engager therapies, and other infectious disease and oncology indications.
Themes: Infectious disease / virology, Immunology and T-cell therapy, Hepatitis delta virus (HDV), Cancer immunotherapy, Masked therapeutics
Fundamentals
- Price$9.78 as of 2026-08-21 close
- Market cap$1.7B as of 2026-08-21
- 1-year return+123.3% 2025-08-21 close $4.38 → 2026-08-21 close $9.78
- P/En/a negative earnings
- Net margin-41.5% as of 2026-08-24
- Gross margin+100.0% as of 2026-08-24
- ROE-14.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-7.6% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)-65.1% SEC XBRL
- Beta1.60 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How VIR compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How VIR BIOTECHNOLOGY INC looks technically
VIR BIOTECHNOLOGY INC (VIR) is trading 18.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 176 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-07-10, pushing above its recent trading range. It is 16.1% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 18.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $9.37 | $9.37 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.23 | $8.23 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 176 trading days ago — a "golden cross", a bullish long-term signal | 176 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 20, below the 25 that marks a real trend) | 19.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($8.62 to $10.08) — its "stochastic" reading is 80 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 79.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.66 | $11.66 |
|---|---|---|
| From the 52-week high | it is 16.1% below its 52-week high (its highest price of the past year) | -16.1% |
| Above the 52-week low | it is 130.1% above its 52-week low (its lowest price of the past year) | +130.1% |
| Below the 52-week high | it is 16.1% below its highest point of the past year | 16.1% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-10, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $141.01 (set on 2021-01-27) | $141.01 |
| Given back of the 52-week move | over the past year its closes ranged ($4.36 to $11.09), and it has given back roughly a quarter of its rise from last year’s low — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.72 to $6.93. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.5% |
| From the all-time high | it is 93.1% below its all-time high | -93.1% |
| Nearest price level | it is trading 1.8% below a resistance level at $9.96 — a price it turned at twice since 2024-12-03, most recently on 2026-05-29. Since 2024-08-21 it has 12 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.8% |
| All-time low | its lowest closing price on record is $4.16 (set on 2025-08-11) | $4.16 |
| Above the all-time low | it is 135.4% above its all-time low | +135.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4552 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4552 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.42 and $9.71 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.42 – $9.06 – $9.71 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges above its 200-day average price (18.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.15× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.1% |
|---|---|---|
| Gap filled | a 3.9% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.5 percentage points (the stock gained 3.8% while the market gained 2.3%) | +1.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 5.2 percentage points (the stock gained 8.3% while the market gained 3.1%) | +5.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 18.3 percentage points (the stock gained 29.4% while the market gained 11.1%) | +18.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 102.8 percentage points (the stock gained 123.3% while the market gained 20.5%) | +102.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.6% of the share price, which is taken to mean a barrier that gives way easily. | +1.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.03 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +8.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $9.19 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +6.4% |
Price levels it has turned at before
VIR last closed at $9.78 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.96 | Resistance | 1.8% above the last close | turned there twice · 2024-12-03 to 2026-05-29 |
| $10.37 | Resistance | 6.0% above the last close | turned there twice · 2024-11-06 to 2026-03-11 |
| $10.56 | Resistance | 8.0% above the last close | turned there twice · 2026-06-30 to 2026-07-09 |
| $8.52 | Support | 12.9% below the last close | turned there twice · 2026-05-19 to 2026-07-28 |
| $8.23 | Support | 15.8% below the last close | turned there three times · 2024-09-16 to 2026-06-11 |
| $7.93 | Support | 18.9% below the last close | turned there three times · 2024-10-16 to 2026-02-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · trendless / choppy (low ADX) · beating the market · Trading above the Ichimoku cloud · Most technical signals bullish | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$21.00 range $15.00 – $30.00; median $20.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VIR
- Consensus EPS estimate-$0.7451 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Drug development and commercialization carry substantial risks with only a small number of R&D programs achieving commercialization; early-stage clinical results may not predict later-stage or larger-scale study outcomes and do not ensure regulatory approval.","Rapid changes and intense competition in the biopharmaceutical environment create ongoing business risks and uncertainties.","The company is unprofitable with a net margin of -638.87% and declining revenue, creating ongoing financing and cash burn risks."]
What changed in the latest 10-Q
AI-assisted comparison of VIR's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to Annual Report on Form 10-K for year ended December 31, 2025 (newer filing dated 2026-05-07, compared to 2024 in older filing)
- Added statement: 'At Vir Bio, we have a bold vision – powering the immune system to transform lives.'
- Added specific details about combination therapy: 'we believe the combination of tobevibart and elebsiran has the potential to be a new standard of care'
- Added sentence: 'we have made available for external partnerships our next-generation preclinical influenza A and B antibodies and antibody-drug conjugates (ADCs) along with our next-generation COVID monoclonal antibodies (mAbs).'
- Added Phase 2 SOLSTICE data presentation at EASL Congress May 27-30, 2026
- Added January 2026 Phase 2 SOLSTICE data showing 77% undetectable HDV RNA at Week 72 and 88% at Week 96
- Added topline data timing: 'ECLIPSE 1 trial are expected in the fourth quarter of 2026' and 'ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027'
- Added Astellas collaboration closure date: 'On April 15, 2026, we closed our global strategic collaboration with Astellas US LLC'
- Added VIR-5500 expansion cohort details: 'Q3W 800/2000/3500 µg/kg step-up dosing in late-line mCRPC'
- Added expectation to 'initiate pivotal Phase 3 trials in 2027'
- Added positive updated Phase 1 data presentation at 2026 ASCO Genitourinary Cancers Symposium
- Added VIR-5818 response data timing: 'response data expected in the second half of 2026'
- Added February 2026 follow-on public offering details: '$172.5 million gross proceeds'
- Added Mark Eisner departure announcement: 'effective April 24, 2026'
- Added 'License and collaboration revenue includes revenues generated from license rights issued to Norgine and GSK, including our profit-share from the sales of sotrovimab'
- Added statement: 'We do not expect to generate any significant revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings and receive approvals'
- Removed:
- Removed reference to Annual Report on Form 10-K for year ended December 31, 2024 (older filing)
- Removed grammatical phrase: 'Our clinical-stage portfolio includes programs for Chronic Hepatitis Delta (CHD) and multiple dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. We also has a preclinical portfolio'
- Removed: 'Our clinical development pipeline consists of investigational therapies targeting hepatitis delta virus (HDV) and various solid tumors.'
- Removed: 'with the first patient dosed in phase 1 clinical studies in July 2025'
- Removed reference to 'Quarterly Report on Form 10-Q for the period ended June 30, 2025'
- Removed detailed CHD trial status: ECLIPSE 1 enrollment completion 'approximately two months ahead of projections', primary completion timing, and detailed trial descriptions for ECLIPSE 1, 2, and 3
- Removed SOLSTICE presentation at AASLD The Liver Meeting 2025 (November 9)
- Removed VIR-5500 combination study detail: 'First patient dosed in Phase 1 clinical study of VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) in first-line mCRPC'
- Removed plan to 'share a comprehensive VIR-5500 data update in late-line patients in the first quarter of 2026'
- Removed VIR-5818 specificity: 'VIR-5818 is the only dual-masked HER2-targeting TCE in clinical development and is being evaluated in multiple tumor types, including metastatic colorectal cancer (CRC).'
- Removed VIR-5525 detailed applications: 'non-small cell lung cancer (NSCLC), CRC, head and neck squamous cell carcinoma (HNSCC) and cutaneous squamous cell carcinoma (cSCC)'
- Removed preclinical pipeline details mentioning 'dAIsY™ (data AI structure and antibody) AI engine'
- Removed sotrovimab EUA revocation discussion and future outlook
- Removed 'Collaboration revenue includes recognition of our profit-share from the sales of sotrovimab pursuant to our 2020 colla' (text truncated in both versions but older version contained this incomplete sentence)
- Reworded:
- Changed 'Chronic Hepatitis Delta' to 'chronic hepatitis delta (CHD)' in overview paragraph
- Changed order of presentation: older filing listed 'VIR-5818' first, newer filing lists 'VIR-5500' first in TCE programs
- Changed 'we believe the combination has the potential' to 'we believe the combination of tobevibart and elebsiran has the potential' (added specific drug names)
- Changed descriptions of VIR-5500 from 'continues to advance through Phase 1 dose escalation' to 'first patient was dosed in the Phase 1 dose-expansion cohorts'
- Removed detailed trial descriptions for ECLIPSE trials and replaced with expected data timelines
- Changed 'preclinical pipeline' section description from mentioning 'undisclosed PRO-XTEN masked TCEs' with 'dAIsY AI engine' to 'a number of PRO-XTEN masked TCEs in preclinical studies directed at clinically validated targets with potential applications across a variety of solid tumors, including lung, colorectal and bladder'
- Changed revenue section structure: older filing began with sotrovimab EUA revocation context, newer filing removed this section entirely
- Notes:
- The older filing text for the revenue section appears truncated at the end ('2020 colla'), so the full comparison of that section may not be complete
- Some content may have been reorganized or rewritten for clarity but represents substantively similar information
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($33822) — 2 selling insiders
- Last 180 days0 buys · 5 sells ($1M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-01. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VIR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VIR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 30,176,511
- Reported value $270,381,542
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VIR had 19,040,209 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VIR had 11.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.24 days to cover at the same settlement.
- Reported short interest (shares) 19,040,209
- Short interest (% of shares outstanding) 11.3%
- Prior settlement (shares) 18,452,974
- Reported change 3.18%
- Days to cover (reported) 12.24
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences
- Regeneron Pharmaceuticals
- Moderna
- BioNTech
- Juno Therapeutics (Celgene)
- Merck
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VIR vs…
VIR ranks in…
Frequently asked questions
What does VIR BIOTECHNOLOGY INC (VIR) do?
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat and prevent serious infectious diseases and cancer. The company leverages its proprietary immunology and virology platforms, including masking and targeted T-cell engagement technologies, to advance product candidates across its pipeline.
What sector is VIR BIOTECHNOLOGY INC (VIR) in?
VIR BIOTECHNOLOGY INC (VIR) is classified in the Health Care sector. Its industry is Clinical-stage immunology and virology therapeutics. It trades on NASDAQ.
Who are VIR BIOTECHNOLOGY INC's (VIR) competitors?
Notable peers of VIR BIOTECHNOLOGY INC (VIR) include Gilead Sciences, Regeneron Pharmaceuticals, Moderna, BioNTech and Juno Therapeutics (Celgene). This peer set is informational only — not financial advice.
Is VIR BIOTECHNOLOGY INC (VIR) overbought or oversold right now?
VIR BIOTECHNOLOGY INC (VIR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VIR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.